Drug Profile

EMP 012

Alternative Names: EMP-012

Latest Information Update: 09 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Empirico
Developer Avance Clinical Pty Ltd; Empirico; GSK
Class Anti-inflammatories; Drug conjugates; Oligonucleotides; Small interfering RNA
Mechanism of Action Gene expression modulators; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Oct 2025 EMP 012 licensed to GSK worldwide
26 Feb 2025 Phase-I clinical trials in Chronic obstructive pulmonary disease in Australia (SC) (ACTRN12624000650594)
26 Feb 2025 Phase-I clinical trials in Chronic obstructive pulmonary disease in United Kingdom (SC) (ACTRN12624000650594)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com